Results 231 to 240 of about 53,329 (292)

Cardiovascular β‐Adrenergic Receptor Distribution and Function: Influence of Species, Sex, Age, and Tissue

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
Estrogen modulates β‐AR signaling in a context‐dependent manner influenced by species, sex, age, tissue, and vascular health, highlighting challenges in translating findings from experimental models to human cardiovascular physiology. ABSTRACT Cardiovascular diseases remain the leading global cause of morbidity and mortality, with notable sex‐specific ...
Basant Elsaid, Irakli Kopaliani, Birgit Zatschler, Ansam Seif, Stephan Speier, Andreas Deussen   +5 more
wiley   +1 more source

Heart–Lung Interactions in Pulmonary Hypertension due to Heart Failure With Preserved Ejection Fraction

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
This review considers heart–lung interactions in pulmonary hypertension due to heart failure with preserved ejection fraction across scales, including organ, tissue, and cell scales. Key knowledge gaps in preclinical disease models, tools for clinical phenotyping, and underlying biological mechanisms are identified for future studies.
Pratima Prabala, Farhan Raza, Naomi C. Chesler   +2 more
wiley   +1 more source

Extracellular Vesicles as Drivers of Lung Endothelial Dysfunction in ARDS: Mechanisms and Therapeutic Opportunities

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
This review summarizes how extracellular vesicles from diverse pulmonary and extrapulmonary sources contribute to endothelial dysfunction in ARDS and evaluates emerging endothelial‐targeted therapies for their potential to mitigate EV‐mediated pathogenic mechanisms.
Mohammed Yaman Al Matni, Patrick Belvitch, Steven M. Dudek, Eleftheria Letsiou   +3 more
wiley   +1 more source

Oxygen Supplementation Improves Oxygen Uptake Kinetics and Exercise Performance in PAH and CTEPH Patients

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
In patients with pulmonary vascular diseases (PAH and CTEPH), supplemental oxygen (FiO2 0.3), compared to room air (FiO2 0.21) improved peak exercise capacity (peak V̇O2), peak sustainable exercise (V̇O2 at GET), and V̇O2 kinetics and the onset of exercise.
Shir Kadosh, Yael Baidats, Andrew M. Jones, Daryl Wilkerson, Ariela Velner, Ronen Reuveny, Michael J. Segel   +6 more
wiley   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1494-1502, June 2026.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

Bibliometric Analysis of Cubebenes and Related Sesquiterpenes: Natural Occurrence, Biosynthesis, Pharmacological Activities, and In‐Silico‐Based Future Therapeutic Potential

eFood, Volume 7, Issue 3, June 2026.
Cubebene‐related sesquiterpenes, found across diverse biological sources, exhibit promising pharmacological activities, including anti‐inflammatory, neuroprotective, and anticancer effects. This review highlights their molecular diversity, ADME profiles, and predicted multitarget interactions, underscoring their therapeutic relevance and potential in ...
Khadija Boualam, Ahmet B. Ortaakarsu, Sohaib Khatib, Mohamed A. Farag, Mansour Sobeh   +4 more
wiley   +1 more source

Aspartame Increases the Risk of Pancreatic Ductal Adenocarcinoma

eFood, Volume 7, Issue 3, June 2026.
Aspartame (APM) is a widely used artificial sweetener associated with various health concerns, including potential links to diabetes, cardiovascular diseases, and an increased risk of cancer. A comprehensive approach incorporating data mining, machine learning, network toxicology, molecular docking, molecular dynamics simulations, and clinical sample ...
Jumin Xie, Wei Fang, Zean Song, Zhang Yu, Ying Zhu, Shaoping Liu   +5 more
wiley   +1 more source

Phosphodiesterase 5 inhibitors: current status and potential applications

Nature Reviews Drug Discovery, 2002
Phosphodiesterase enzymes convert cyclic GMP and cyclic AMP to the corresponding nucleotide monophosphates. Phosphodiesterase 5 (PDE5) inhibition is now a widely accepted and efficacious therapeutic option for the treatment of erectile dysfunction in men,
David P Rotella
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Phosphodiesterase inhibitors

Current Anaesthesia & Critical Care, 1993
Despite the justifiable concern about the use of oral cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitors, the intravenous preparations are clearly effective in the treatment of acute heart failure, whether it occurs de novo or complicating chronic congestive heart failure (CHF), and in low output states following cardiac surgery ...
R, Andrews, A J, Cowley
  +6 more sources

Phosphodiesterase inhibitors and the eye

Clinical & Experimental Ophthalmology, 2009
AbstractPhosphodiesterase type 5 (PDE5) inhibitors are effective oral treatments for erectile dysfunction and have become one of the most widely prescribed medications worldwide. The mechanism of action is to reduce the degradation of cyclic GMP (cGMP) potentiating the effect of nitric oxide in the corpus cavernosum and allowing erectile function to ...
Nathan M, Kerr, Helen V, Danesh-Meyer
openaire   +2 more sources